From clinical to biological definitions of neurological diseases

Karen O’Leary

DOI: https://doi.org/10.1038/s41591-024-03387-8

IF: 82.9

2024-12-14

Nature Medicine

Abstract:February saw the release of revised criteria for the diagnosis and staging of Alzheimer's disease (AD) by the Alzheimer's Association Workgroup, to align with recent scientific advances — including the approval of therapies that target AD pathology, and the development of reliable and accessible biomarkers. The new criteria define 'core' (specific to AD) and 'non-core' biofluid and imaging-based biomarkers; diagnosis now relies on the presence of amyloid and tau, with clinical diagnosis of dementia alone being insufficient for AD diagnosis. Although they are not without controversy, these new criteria are broadly accepted by clinical societies and reflect a shift toward biological definitions of neurological diseases beyond AD. Indeed, two frameworks were published this year that outline biological criteria for the staging of Parkinson's disease — although, unlike those for AD, these are not yet widely accepted or ready for clinical use. Overall, this biological reframing of neurological conditions should better address the priorities of research and clinical care. Original references: Alzheimers Dement . 20 , 5143–5169 (2024); Nat Med . 30 , 2121–2124 (2024); Lancet 23 , 191–204 (2024); Lancet 23 , 178–190 (2024)

biochemistry & molecular biology,cell biology,medicine, research & experimental